PreComb Therapeutics AG from the canton of Zurich has secured investment of 2.2 million francs in a seed financing round. The round was led by the Austrian subsidiary of the Hong Kong investment company Kinled and the Zurich-based FiveT Group.
PreComb has developed 3D technology for the functional patient-specific drug testing of cancer therapies. This point-of-care technology enables clinical institutions to test a large number of therapies directly. While a press release explains that personalized therapies have become a prime focus, current patient-specific molecular and histopathological information is not sufficient to enable personalized medicine for most patients.
“In recent years, we have seen a change of dogma in the treatment of cancer,” said Jens M. Kelm, co-founder and CEO of PreComb. “However, to achieve the full benefit of personalized medicine decisions for most patients, we need fully translatable testing platforms that directly assess individual drug sensitivity and resistance and can be implemented on-site in the clinic.” The PreComb test platform enables clinical institutions to test a large number of therapies directly on 3D microtumors generated from patient tumors.
“We look forward to supporting PreComb to help cancer patients receive the most promising therapies and take advantage of the immense opportunities ahead,” noted Patrick Aisher, managing partner at Kinled Austria. He has joined the Board of Directors of PreComb.